A5079629995- Endometrial and Cervical Cancer Treatments
- Ovarian cancer diagnosis and treatment
- Cancer-related molecular mechanisms research
- Cancer Genomics and Diagnostics
- Cervical Cancer and HPV Research
- Radiomics and Machine Learning in Medical Imaging
- Reproductive System and Pregnancy
- Circular RNAs in diseases
- MRI in cancer diagnosis
- Epigenetics and DNA Methylation
- Endometriosis Research and Treatment
- 14-3-3 protein interactions
- Estrogen and related hormone effects
- RNA Research and Splicing
- Angiogenesis and VEGF in Cancer
- Cytokine Signaling Pathways and Interactions
- Genetic factors in colorectal cancer
- RNA modifications and cancer
- MicroRNA in disease regulation
- Sex and Gender in Healthcare
- Lung Cancer Treatments and Mutations
- Cancer, Hypoxia, and Metabolism
- Cancer Cells and Metastasis
- Lung Cancer Research Studies
- Sarcoma Diagnosis and Treatment
Haukeland University Hospital
2016-2025
University of Bergen
2016-2025
University of Alabama at Birmingham
2021
Norwegian University of Life Sciences
2014
Mayo Clinic
2013
Brigham and Women's Hospital
2013
Radboud University Medical Center
2013
Radboud University Nijmegen
2013
Harvard University
2013
Moffitt Cancer Center
2013
Epithelial ovarian cancer (EOC) has a heritable component that remains to be fully characterized. Most identified common susceptibility variants lie in non-protein-coding sequences. We hypothesized the 3′ untranslated region at putative microRNA (miRNA)-binding sites represent functional targets influence EOC susceptibility. Here, we evaluate association between 767 miRNA-related single-nucleotide polymorphisms (miRSNPs) and risk 18,174 cases 26,134 controls from 43 studies genotyped through...
Despite successful implementation of drugs targeting the human epidermal growth factor receptor 2 (HER2) in breast and gastric cancers, potential HER2 as a therapeutic target other cancers has been less studied, including endometrial cancer. We investigated expression levels (ERBB2) large cohort cancer lesions, also complex atypical hyperplasia metastatic lesions. 67 precursor 790 primary 383 lesions were for relation to clinicopathologic features outcome. Protein assessed by...
// Ingvild Løberg Tangen 1, 2 , Therese Bredholt Onyango Reidun Kopperud Anna Berg Mari K. Halle Anne M. Øyan 3, 4 Henrica M.J. Werner Jone Trovik Karl Henning Kalland Helga B. Salvesen 2, * Camilla Krakstad 5, 1 Centre for Cancer Biomarkers, Department of Clinical Science, University Bergen, Norway Gynecology and Obstetrics, Haukeland Hospital, 3 Medicine, Microbiology, 5 Biomedicine, These authors contributed equally to this work Correspondence to: Krakstad, email:...
// Anna Berg 1,2 , Erling A. Hoivik Siv Mjøs Frederik Holst Henrica M. J. Werner Ingvild L. Tangen Amaro Taylor-Weiner 7,8,9 William Gibson Kanthida Kusonmano 1,2,3 Elisabeth Wik 4,5 Jone Trovik Mari K. Halle Anne Øyan 1,6 Karl-Henning Kalland Andrew D. Cherniack 7 Rameen Beroukhim Ingunn Stefansson Gordon B. Mills 10 Camilla Krakstad and Helga Salvesen 1,2* 1 Department of Clinical Science, Center for Cancer Biomarkers, University Bergen, Norway 2 Gynecology Obstetrics,...
Recent identification of a specific role HSF1 in cancer progression has led to new relevance as both prognostic and predictive marker. The endometrial so far been unexplored. A total 823 lesions from carcinoma precursors, primary tumours metastases were prospectively collected explored for protein expression relation established markers aggressive disease survival. Transcriptional alterations related level investigated by microarray analysis 224 freshly frozen samples parallel. High is...
PD-L1 and PD-1 are predictive markers for immunotherapy increasingly relevant in endometrial cancer. The reported fraction of positive primary tumors has been inconsistent. We investigated the expression tumors, also stratified by MSI. As is foremost metastatic disease, was assessed corresponding lesions.PD-L1 a prospective, population based cancer cohort 700 patients with lesions from 68 74 respectively. Fresh tissue used gene analysis.In expressed 59% 63%, respectively, but no impact on...
Human papillomavirus (HPV)-associated cervical cancer is a leading cause of deaths in women. Here we present an integrated multi-omic analysis 643 squamous cell carcinomas (CSCC, the most common histological variant cancer), representing patient populations from USA, Europe and Sub-Saharan Africa identify two CSCC subtypes (C1 C2) with differing prognosis. C1 C2 tumours can be driven by either HPV types (16 18) while HPV16 HPV18 are overrepresented among respectively, prognostic difference...
High-grade neuroendocrine cervical cancers (NETc) are exceedingly rare, highly aggressive tumors. We analyzed 64 NETc tumor samples by whole-exome sequencing (WES). Human papillomavirus DNA was detected in 65.6% (42/64) of the Recurrent mutations were identified PIK3CA, KMT2D/MLL2, K-RAS, ARID1A, NOTCH2, and RPL10. The top mutated genes included RB1, PTEN, KMT2D / MLL2, WDFY3, a gene not yet implicated NETc. Somatic CNV analysis two copy number gains (3q27.1 19q13.12) five losses...
Abstract Background Effective diagnostic tools for prompt identification of high-risk locally advanced cervical cancer (LACC) patients are needed to facilitate early, individualized treatment. The aim this work was assess temporal changes in tumor radiomics (delta radiomics) from T2-weighted imaging (T2WI) during concurrent chemoradiotherapy (CCRT) LACC patients, and their association with progression-free survival (PFS). Furthermore, develop, validate, compare delta- pretreatment radiomic...
Abstract Pelvic MRI is essential for evaluating local and regional tumor extent in uterine cervical cancer (CC). Tumor microstructure captured by diffusion-weighted imaging (DWI) apparent diffusion coefficient (ADC) markers may be closely linked to prognosis CC. Purpose To explore whether primary ADC predict survival Material methods CC patients ( n = 179) diagnosed during 2009–2020 with MRI-assessed maximum size ≥ 2 cm were included this retrospective single-center study. Two radiologists...
// Camilla Krakstad 1,2 , Ingvild L. Tangen Erling A. Hoivik Mari K. Halle Anna Berg Henrica M. Werner Maria B. Ræder Kanthida Kusonmano 1,2,3 June X. Zou 4 Anne Øyan 5,6 Ingunn Stefansson 5,7 Jone Trovik Karl-Henning Kalland Hong-Wu Chen and Helga Salvesen 1 Centre for Cancer Biomarkers, Department of Clinical Science, University Bergen, Bergen, Norway 2 Gynecology Obstetrics, Haukeland Hospital, 3 Computational Biology Unit, Internal Medicine Biochemistry Molecular...
Uterine cervical cancer (CC) is the most common gynecologic malignancy worldwide. Whole-volume radiomic profiling from pelvic MRI may yield prognostic markers for tailoring treatment in CC. However, relies on manual tumor segmentation which unfeasible clinic. We present a fully automatic method 3D of primary CC lesions using state-of-the-art deep learning (DL) techniques. In 131 patients, was manually segmented T2-weighted by two radiologists (R1, R2). Patients were separated into...
Cancers arise through accumulating genetic and epigenetic alterations, considered relevant for phenotype approaches to targeting new therapies. We investigated a unique collection of endometrial cancer precursor samples clinically annotated primary metastatic lesions two evolutionary functionally related transcription factors, CCCTC-binding factor (zinc finger protein) (CTCF) its paralogue CTCF-like factor, also denoted Brother the Regulator Imprinted Sites (CTCFL/BORIS). CTCF, chromatin...
Stathmin is a prognostic marker in many cancers, including endometrial cancer. Preclinical studies, predominantly breast cancer, have suggested that stathmin may additionally be predictive for response to paclitaxel. We first evaluated the paclitaxel cancer cell lines before and after knock-down. Subsequently we investigated clinical containing chemotherapy metastatic relation protein level tumors. was also determined lesions, analyzing changes biomarker status on disease progression....
// Anna Berg 1, 2 , Kristine E. Fasmer 3 Karen K. Mauland Sigmund Ytre-Hauge 3, 4 Erling A. Hoivik Jenny Husby Ingvild L. Tangen Jone Trovik Mari Halle Kathrine Woie Line Bjørge Atle Bjørnerud 5, 6 Helga B. Salvesen Henrica M. J. Werner Camilla Krakstad 2, 7, * Ingfrid S. Haldorsen 4, 1 Center for Cancer Biomarkers, Department of Clinical Science, University Bergen, Norway Gynecology and Obstetrics, Haukeland Hospital, Radiology, Section Medicine, 5 Physics, Oslo, The...
Abstract Prognostication is critical for accurate diagnosis and tailored treatment in endometrial cancer (EC). We employed radiogenomics to integrate preoperative magnetic resonance imaging (MRI, n = 487 patients) with histologic-, transcriptomic- molecular biomarkers ( 550 aiming identify aggressive tumor features a study including 866 EC patients. Whole-volume radiomic profiling from manually (radiologists) segmented tumors 138 yielded clusters identifying patients high-risk histological...
Advanced cervical cancer carries a particularly poor prognosis, and few treatment options exist. Identification of effective molecular markers is vital to improve the individualisation treatment. We investigated transcriptional data from carcinomas related patient survival recurrence identify potential drivers for aggressive disease.Primary tumour RNA-sequencing profiles 20 patients with 53 cured disease were compared. Protein levels prognostic impact selected identified by...
Background Despite being the most common pelvic gynecologic malignancy in industrialized countries, no targeted therapies are available for patients with metastatic endometrial carcinoma. In order to improve treatment, underlying molecular characteristics of primary and disease must be explored. Methodology/Principal Findings We utilized mass spectrometric-based mutation detection technology OncoMap define types frequency point somatic mutations cancer. 67 tumors, 15 metastases corresponding...
Abstract Background: Genome-wide association studies (GWAS) have identified more than 100 genetic loci for various cancers. However, only one is endometrial cancer. Methods: We conducted a three-stage GWAS including 8,492 cancer cases and 16,596 controls. After analyzing 585,963 single-nucleotide polymorphisms (SNP) in 832 2,682 controls (stage I) from the Shanghai Endometrial Cancer Genetics Study, we selected top 106 SNPs silico replication among 1,265 5,190 Australian/British II). Nine...